Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)
Conditions
Interventions
TAK-994
Placebo
Locations
78
United States
Wright Clinical Research
Alabaster, Alabama, United States
Mayo Clinic Arizona
Phoenix, Arizona, United States
CITrials - Bellflower
Bellflower, California, United States
Santa Monica Clinical Trials
Los Angeles, California, United States
Stanford School of Medicine
Redwood City, California, United States
Pacific Research Network, Inc
San Diego, California, United States
Start Date
May 27, 2020
Primary Completion Date
November 5, 2021
Completion Date
November 5, 2021
Last Updated
October 29, 2024
NCT07363720
NCT06462404
Lead Sponsor
Takeda
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions